Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 2/2018

01-02-2018 | Short Communication

Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur

Authors: S. L. Greenspan, K. Vujevich, C. Britton, A. Herradura, G. Gruen, I. Tarkin, P. Siska, B. Hamlin, S. Perera

Published in: Osteoporosis International | Issue 2/2018

Login to get access

Abstract

Summary

The Fracture Improvement with Teriparatide (Fix-IT) study randomized 13 women with an atypical femur fracture to immediate vs delayed teriparatide therapy; all were followed for 12 months. Results suggested a trend for superior healing and lesser bone mineral density declines in the immediate vs delayed group with no differences in adverse events.

Purpose

Little clinical data are available on the use of teriparatide for the treatment of bisphosphonate-associated atypical femur fractures (AFF). The goal of the Fix-IT study was to determine if immediate therapy with teriparatide was superior for fracture healing after an AFF compared to a 6-month delay in teriparatide therapy.

Methods

This randomized pilot clinical trial included 13 women with an AFF who were randomized to immediate teriparatide vs a delay of 6 months. All were followed for 12 months on teriparatide. The primary outcomes included individual and composite measures of radiologic bone healing (scored 1 point [no healing] to 4 points [complete healing]) at 6 and 12 months. Secondary outcomes included bone mineral density of the unfractured contralateral hip, spine, 1/3 distal radius, and adverse events.

Results

We found there was a trend for superior healing with the composite score (12.6 vs 11.2 at 6 months and 15.4 vs 13.2 at 12 months), and lesser bone mineral density declines at the 1/3 distal radius (12-month change − 1.9 vs − 6.1%) in the immediate vs the delayed group. There were no differences in adverse events. There was one implant failure in the delayed group.

Conclusions

There is a preliminary signal for greater improvements with immediate teriparatide therapy vs delayed therapy. However, because an AFF is a rare event, and only a small number of patients were included, the results must be interpreted with caution.
Appendix
Available only for authorised users
Literature
1.
Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Suttorp MJ, Motala A, Ewing B, Roth B, Shanman R et al (2012) AHRQ comparative effectiveness reviews. In: Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 Report. edn. Rockville (MD): Agency for Healthcare Research and Quality (US)
2.
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res : Off J Am Soc Bone Miner Res 29(1):1–23CrossRef
3.
Park-Wyllie LY, Mamdani MM, Juurlink DA, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305(8):783–789CrossRef
4.
Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphoshonate use and atypical fractures of the femoral shaft. N Engl J Med 364(18):1728–1737CrossRef
5.
Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res : Off J Am Soc Bone Miner Res 25(11):2267–2294CrossRef
6.
Im GI, Lee SH (2015) Effect of teriparatide on healing of atypical femoral fractures: a systemic review. J Bone Metab 22(4):183–189CrossRef
7.
Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 52(1):360–365CrossRef
8.
Kim JT, Jeong HJ, Lee SJ, Kim HJ, Yoo JJ (2016) Adjuvant teriparatide therapy for surgical treatment of femoral fractures; does it work? Hip Pelvis 28(3):148–156CrossRef
9.
Mastaglia SR, Aguilar G, Oliveri B (2016) Teriparatide for the rapid resolution of delayed healing of atypical fractures associated with long-term bisphosphonate use. Eur J Rheumatol 3(2):87–90CrossRef
10.
Bukata SV, Puzas JE (2010) Orthopedic uses of teriparatide. Curr Osteoporos Rep 8(1):28–33CrossRef
11.
Miyakoshi N, Aizawa T, Sasaki S, Ando S, Maekawa S, Aonuma H, Tsuchie H, Sasaki H, Kasukawa Y, Shimada Y (2015) Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. J Bone Miner Metab 33(5):553–559CrossRef
12.
Rigler SK, Studenski S, Wallace D, Recker D, Duncan PW (2002) Co-morbidity adjustment for functional outcomes in communtiy-dwelling older adults. ClinRehabil 16(4):420–428
13.
Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483CrossRef
14.
Greenspan A (2011) Orthopedic imaging: a practical approach. Lippincott Williams & Wilkins, Philadelphia
15.
Varney LF, Parker RA, Vincelette A, Greenspan SL (1999) Classification of osteoporosis and osteopenia in postmenopausal women is dependent on site-specific analysis. J Clin Densitom 2:275–283CrossRef
16.
Kim SC, Kim DH, Mogun H, Eddings W, Polinski JM, Franklin JM, Solomon DH (2016) Impact of the U.S. Food and Drug Administration’s safety-related announcements on the use of bisphosphonates after hip fracture. J Bone Miner Res : Off J Am Soc Bone Miner Res 31(8):1536–1540CrossRef
17.
Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res : Off J Am Soc Bone Miner Res 29(9):1929–1937CrossRef
18.
Khosla S, Shane E (2016) A crisis in the treatment of osteoporosis. J Bone Miner Res : Off J Am Soc Bone Miner Res 31(8):1485–1487CrossRef
19.
Jha S, Wang Z, Laucis N, Bhattacharyya T (2015) Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996–2012: an ecological analysis. J Bone Miner Res : Off J Am Soc Bone Miner Res 30(12):2179–2187CrossRef
20.
Watts NB, Aggers D, McCarthy EF, Savage T, Martinez S, Patterson R, Carrithers E, Miller PD (2017) Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. J Bone Miner Res : Off J Am Soc Bone Miner Res 32(5):1027–1033CrossRef
21.
Ellegaard M, Kringelbach T, Syberg S, Petersen S, Beck Jensen JE, Bruel A, Jorgensen NR, Schwarz P (2013) The effect of PTH(1-34) on fracture healing during different loading conditions. J Bone Miner Res : Off J Am Soc Bone Miner Res 28(10):2145–2155CrossRef
Metadata
Title
Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur
Authors
S. L. Greenspan
K. Vujevich
C. Britton
A. Herradura
G. Gruen
I. Tarkin
P. Siska
B. Hamlin
S. Perera
Publication date
01-02-2018
Publisher
Springer London
Published in
Osteoporosis International / Issue 2/2018
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-017-4286-7

Other articles of this Issue 2/2018

Osteoporosis International 2/2018 Go to the issue

Review

Exercise to improve functional outcomes in persons with osteoporosis: a systematic review and meta-analysis

Original Article

Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials?

Review

Osteoporosis and bone mineral density in patients with Wilson’s disease: a systematic review and meta-analysis

Original Article

The effect of insulin on bone mineral density among women with type 2 diabetes: a SWAN Pharmacoepidemiology study

Review

The effect of exercise on bone mineral density in adult cancer survivors: a systematic review and meta-analysis

Original Article

Geisinger high-risk osteoporosis clinic (HiROC): 2013–2015 FLS performance analysis